Alternative treatment of chemoresistant, recurrent or advanced ovarian cancer. Part I

Jacek R. Wilczyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2011
vol. 10

Send email

Copy url:

abstract:

Review paper

Alternative treatment of chemoresistant, recurrent or advanced ovarian cancer. Part I

Jacek R. Wilczyński

Przegląd Menopauzalny 2011; 3: 181–186

Online publish date: 2011/07/04

View full text Get citation

Despite improved surgical treatment and modern chemotherapy the prognosis in advanced ovarian cancer is poor, mainly due to observed tumour chemoresistance against protocols based on cisplatin and taxanes. The paper describes different forms of immunopotentiation of the anti-cancer host response based on immunotherapy with the use of monoclonal antibodies, cytokines, dendritic cell vaccines or activated T cells. Immunotherapy used separately or in combination with chemotherapy could, at least to some extent, enhance the efficacy of ovarian cancer treatment.

keywords:

Alternative treatment of chemoresistant, recurrent or advanced ovarian cancer. Part I

Jacek R. Wilczyński

ovarian cancer, monoclonal antibodies, cytokines, dendritic cells, T lymphocytes